Dynavax Technologies (NASDAQ:DVAX) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Dynavax Technologies (NASDAQ:DVAX) in a research report sent to investors on Friday,Benzinga reports. HC Wainwright currently has a $29.00 target price on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Dynavax Technologies’ Q4 2024 earnings at $0.04 EPS, FY2024 earnings at $0.18 EPS and FY2025 earnings at $0.26 EPS.

Separately, The Goldman Sachs Group cut their target price on shares of Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating for the company in a research note on Thursday, August 8th.

Dynavax Technologies Price Performance

Shares of Dynavax Technologies stock opened at $13.66 on Friday. Dynavax Technologies has a twelve month low of $9.74 and a twelve month high of $15.01. The company has a debt-to-equity ratio of 0.35, a quick ratio of 13.18 and a current ratio of 14.18. The firm has a market cap of $1.79 billion, a P/E ratio of 105.01 and a beta of 1.34. The firm’s 50-day simple moving average is $11.16 and its 200-day simple moving average is $11.24.

Hedge Funds Weigh In On Dynavax Technologies

A number of institutional investors have recently modified their holdings of DVAX. Mizuho Markets Americas LLC raised its position in shares of Dynavax Technologies by 16.9% during the first quarter. Mizuho Markets Americas LLC now owns 852,057 shares of the biopharmaceutical company’s stock worth $10,574,000 after acquiring an additional 123,300 shares during the last quarter. Assenagon Asset Management S.A. bought a new position in Dynavax Technologies in the third quarter valued at about $8,291,000. Millennium Management LLC acquired a new stake in Dynavax Technologies in the second quarter worth about $17,615,000. Vanguard Group Inc. raised its holdings in Dynavax Technologies by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 9,402,246 shares of the biopharmaceutical company’s stock worth $116,682,000 after purchasing an additional 126,458 shares during the last quarter. Finally, Bank of Montreal Can lifted its position in Dynavax Technologies by 15.2% during the 2nd quarter. Bank of Montreal Can now owns 994,632 shares of the biopharmaceutical company’s stock valued at $11,309,000 after purchasing an additional 130,893 shares during the period. 96.96% of the stock is owned by institutional investors.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.